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Abstract
Background: Malaria has always been a major public health problem in Yemen. Several studies in
developing countries have demonstrated ineffective and poor quality drugs including antimalarials.
Therefore, quality assessment of antimalarial drugs is of crucial importance. This study aimed to
assess the quality of antimalarials (chloroquine and sulfadoxine/pyrimethamine) available in Yemen
and to determine whether the quality of these products was related to the level of the distribution
chain at which the samples were collected or related to the manufacturers.
Methods: Four samples from each antimalarial product were collected from each of the various
levels of the distribution chain. One sample was kept with the research team. Two were tested at
Sana'a and Aden Drug Quality Control Laboratories. The fourth was sent to the Centre for Quality
Assurance of Medicines in Potchefstroom, South Africa, for analysis. Quality indicators measured
were the content of the active ingredient and dissolution rate (for tablets only) in comparison to
standard specifications for these products in the relevant pharmacopoeia.
Results:  The results identified several problems of sub-standard products within the drug
distribution chain. They included high and low failures in ingredient content for chloroquine tablets
and chloroquine syrup. There was some dissolution failure for chloroquine tablets, and high
sulfadoxine/pyrimethamine tablets dissolution failures. Failures with the dissolution of the
pyrimethamine were found at most of the collection points. No clear relationship neither between
the quality products and the level of the distribution chain, nor between locally manufactured and
imported products was observed.
Conclusion: There are sub-standard antimalarial products circulating within the drug distribution
chains in the country, which will have serious implications on the reduced therapeutic effectiveness
and on the development of drug resistance. This appears to be due to non-compliance with Good
Manufacturing Practice guidelines by manufacturers in the production of the antimalarials.
Background
Malaria has always been a major public health problem in
Yemen. About half of the population are at risk of malaria
and there are several hundred deaths every year [1].
A preliminary, exploratory meeting of experts and other
concerned parties was held in Geneva in October 1998.
The meeting concluded, that poor quality antimalarials
(AMs) posed a problem for malaria control, and therefore
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to public health, especially in countries where there is lit-
tle or no drug regulatory infrastructure.
Treatment failure, associated with drug resistance may
also be due to poor quality products, instability of prod-
ucts, or the use of counterfeit products. Several WHO-
sponsored studies have demonstrated significantly the
instability of products such as ergometrine, [2-4] and
other essential medicines, during transport by sea, and
also during road transport inland [5,6]. A WHO docu-
ment on accelerated stability studies under simulated
tropical conditions provides some indication of intrinsic
stability of commonly used drugs [7]. A study in Sudan on
stability of drugs in the tropics showed a considerable
reduction in the concentration of the liquid dosage forms
of certain preparations, whereas solid dosage forms were
relatively stable [8]. A recent study in selected African
countries identified several significant problems of sub-
standard AM products within the drug distribution chain
[9].
The problem of counterfeit drugs is well recognized in dif-
ferent parts of the developing world [10]. The use of inef-
fective and products of poor quality will not only
endanger therapeutic treatment but also erode public con-
fidence in national health programmes.
In most countries the quality of AMs is rarely independ-
ently evaluated and the local capacity for independent
drug-quality assurance is worst where the disease burden
is the highest. AMs of poor quality might contribute to the
emergence of resistance. It is therefore, important to con-
sider product quality when dealing with the problem of
antimalarial resistance.
In Yemen, drug registration is overseen by the Supreme
Board of Drugs and Medical Appliances (SBD&MA).
There are two national reference laboratories for drug
quality control, one in Sana'a and the other in Aden.
The Drug Fund (DF) tender for public sector drugs cen-
trally. Suppliers deliver drugs to the four public regional
stores in the country. Lahej Governorate obtain their med-
ical supplies from Aden regional medical stores (RMS)
through Lahej central medical stores (CMS). The existing
district medical stores receive supplies from Lahej CMS
and distribute them to the health facilities within their
district. Sometimes drugs may be supplied directly from
Lahej CMS to the health facilities.
In view of the need to clarify the nature and magnitude of
the problem of AM quality in the country, it was decided
to carry out a study in a selected Governorate to evaluate
the extent of the problem and guide designing suitable
intervention strategies.
This study aimed at assessing the quality of the commonly
used AMs in Yemen, particularly, chloroquine and sulf-
adoxine/pyrimethamine and to determine whether the
sub-standard quality of these products was related to the
level of the distribution chain at which the samples were
collected or to the manufacturer. It also aimed at evaluat-
ing the performance of the national reference laborato-
ries, by comparing their results to those obtained from an
international reference laboratory in South Africa.
Methods
Chloroquine phosphate 250 mg tablets (CQT), chloro-
quine base 50 mg/5 ml syrup (CQS), and sulfadoxine/
pyrimethamine 500 mg/25 mg tablets (SPT) were sam-
pled and evaluated. They were chosen because they are the
most widely used AMs in Yemen and included in Yemen
Treatment Guidelines and Essential Drugs List [11].
The study adopted the same methods used by the WHO to
assess the quality of antimalarials in malaria endemic
countries [9]. Therefore, samples were collected at various
levels of the drug distribution chain in the public and pri-
vate sector in Lahej Governorate, which is one of the high-
est malaria-endemic areas in Yemen. Samples were
collected from 3 medical stores, the Governorate hospital,
4 district hospitals/health centres, 9 health units and 5
private sector pharmacies. The total samples collected
from all levels of the drug distribution were 15 CQS, 25
CQT, and 10 SPT, for details see Table 1.
The sampling was performed as follows. Four districts, in
addition to the capital of the governorate, were selected by
simple random sampling. Samples from the Governorate
hospital and the hospitals of the four districts were stud-
ied (there is only one hospital or health centre in each dis-
trict). Nine health units which are working and easy to
reach were chosen (most health units are difficult to reach
because of long distance or bad roads). Samples were also
collected from only one district medical stores because
there are no medical stores in the other districts as the hos-
pital/health centre store functioning as a hospital store,
pharmacy and also supply the district health units.
Samples were also collected from 5 private pharmacies in
the governorate.
One sample was collected from the governorate capital
and one sample from each of the studied districts. The
pharmacies were selected by systematic random sampling.
Chloroquine syrup in both public and private sector was
available in bottles of 100 or 120 ml. Chloroquine tablets
were available in strips of 10 tablets or tins/bottles of
1000 tablets. Sulfadoxine/pyrimethamine tablets were
present in strips of 3 or 10 tablets each.Malaria Journal 2005, 4:28 http://www.malariajournal.com/content/4/1/28
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Four bottles of chloroquine syrup, four samples of chloro-
quine tablets (20 tablets/sample) and four samples of sul-
fadoxine/pyrimethamine tablets (20 tablets/sample) were
taken by convenience sampling. Each preparation was
from the same batch.
Four samples from each batch were collected from each
private community pharmacy/drug store and each level of
the public drug distribution chain. These samples were
divided as follow:
One was kept with the research team; one was tested at
Sana'a Drug Quality Control Laboratory (Sana'a DQCL);
one was tested at Aden Drug Quality Control Laboratory
(Aden DQCL); one was sent to Eastern Mediterranean
Regional office of the World Health Organization (WHO/
EMRO) and then forwarded to the Centre for Quality
Assurance of Medicine (CENQAM) in Potchefstroom, in
South Africa for analysis.
The following information was recorded during field sur-
vey for each drug sample on a serially numbered data col-
lection form: location of sample collection point (name
of the facility); facility type; name of drug (brand or
generic); strength and dosage form; date of manufacture;
date of expiry; description of packaging material and any
remarks on storage; date of sample collection; name of
person in charge of institution and name of person col-
lecting the sample
The collected samples of tablets were transferred from
their original containers into amber glass bottles with
screw cap seals. Syrups were left in their original contain-
ers. The containers were carefully labeled at the point of
collection with sticker containing the same information
on the original container, particularly, drug name, batch
number, facility name, sampling date and sample form
number. Each sticker was given a unique sampling identi-
fication code.
All testing was carried out at Sana'a and Aden DQCLs. For
verification the same samples were tested in CENQAM
Laboratories. Samples were analysed according to phar-
macopoeial specifications to assess the quality of the
products. The quality indicators measured were the con-
tent of the active ingredient for syrup, and dissolution and
content for tablets.
There is no analytical monograph in the United States
Pharmacopoeia (USP) or British Pharmacopoeia (BP) for
the assay of CQS. CENQAM used a high pressure liquid
chromatography (HPLC) method which was developed
and validated in-house [9]. Sana'a and Aden DQCLs used
the method of PHARCO Pharmaceuticals-an Egyptian
pharmaceutical manufacturer. In this method the absorb-
ance of both standard and test solutions was measured by
UV-spectroscopy at 329 nm.
The content of CQ in tablets was determined by UV-spec-
trophotometry in accordance with an adapted method for
CQT of the USP 2003:424. The method consists of record-
ing the UV absorbance of the sample at a wavelength of
343 nm and comparing it to the absorbance of a reference
standard in a concentration range representing a 100%
label claim at the same wavelength.
The content of SP was determined by means of the HPLC
method for the assay of SPT described in the USP
2003:1734. The mobile phase was adjusted to satisfy the
system suitability criteria of the USP for chromatographic
systems.
The general method and apparatus of the USP were used
for testing the dissolution characteristics of both CQT and
SPT according to their respective dissolution monographs.
Table 1: Summary sample collection grid for quality study
Facilities # CQT CQS SPT Total
R M S 11113
G M S 11113
D M S 12--2
G H 11113
RH/HC 4 6 (1 exp) 3 (2 exp) 2 11
H U 994  ( 1  e x p ) -1 3
P H 55551 5
T o t a l 2 22 51 51 05 0
RMS = Regional Medical Store, Aden;
GMS = Central Medical Stores, Lahej Governorate DMS = District Medical Stores; GH = Governorate General Hospital; RH/HC = Rural Hospital/
Health Centre; HU = Health Unit; PP = Private Pharmacy/Drug Store; exp = Expired CQT = Chloroquine tablets; CQS = Chloroquine syrup; SPT= 
Sulfadoxine Pyrimethamine tablets.Malaria Journal 2005, 4:28 http://www.malariajournal.com/content/4/1/28
Page 4 of 7
(page number not for citation purposes)
The dissolution parameters for CQT in the USP 2003:424
and for SPT in the USP 2003:1734 were followed.
Results
Table 2 shows the laboratory results of CQS tested in the
three reference laboratories. As CQS has no official mon-
ograph in the USP or BP, an acceptance criteria of 90–110
of the label claim was adopted. Only one product did not
comply with the adapted criteria and tested too high i.e.
had some "high" content failure. This high percentage
ingredient failure (116.2%) was recorded at Tor-Albeh
rural hospital/health centre and manufactured by
YEDCO, Republic of Yemen.
The acceptance criteria for CQT (phosphate) in the USP
are 93–107% of the stated amount per unit. Most failures
were "low" failures i.e. sample contents below the mini-
mum recommended levels for the products The lowest
percentage failures in ingredient content were recorded
for 3 products at Al-Raga health unit in Tor-Albaheh dis-
trict, central medical stores in Lahej and regional medical
stores in Aden. The three products were manufactured by
YEDCO, Republic of Yemen. The highest percentage
ingredient contents failure were found at Al-Mosimir rural
hospital and Akan health unit in Al-Mosimir district. They
were manufactured by YEDCO, Republic of Yemen, and
PHARMED, the Netherlands respectively.
Dissolution testing was done on 6 units and % relative
standard deviation (% RSD) of < 5 % was observed for
most of the products tested. The exceptions were CQT/
HU-7 (5.3%) and CQT/HU-9 (7.6%).
The dissolution acceptance criteria for CQT of the USP
were applied. CQT have a Q-value (the quantity of
dissolved active specified in the monograph, expressed as
a percentage of the labeled content) of 75% in 45 minutes
and, according to the acceptance table of USP 2003:2161,
the dissolution of each of the six units tested should not
be less than 80% (Q+5). The product found at Al-Megha-
fah health unit, Toben district (CQT/HU-7) and the prod-
uct found at Al-Fiosh health unit, Toben district (CQT/
HU-9) did not comply with the criteria. These two prod-
ucts are manufactured by ALKALOIDA Chemical Co. Ltd.,
Hungary (See Additional file 1, showing the results of
chloroquine tablets testing in the three reference
laboratories).
The content criteria for SPT in the USP 2003:1734 are 90–
110 of the label claims for both actives. The percentage of
SP contents in tablets for all studied SPT samples com-
plied with the criteria with respect to both actives.
Dissolution testing was done on 6 units and a high % RSD
was observed for pyrimethamine in some of the products
Table 2: The laboratory results of chloroquine syrup tested at the three reference laboratories
CHLOROQUINE SYRUP (Limit: 90–110%)
Code CENQAM DQCL-Sana'a DQCL-Aden
Assay (%) % RSD Assay (%) % RSD Assay (%) % RSD
CQS/RMS 104.1 3.20 96.20 0.60 102.0 0.36
CQS/SMS 105.7 1.10 100.5 1.01 100.5 3.71
CQS/LGH 109.0 3.20 99.4 1.94 101.2 1.77
CQS/MRH-1 91.1 3.50 101.2 2.65 102.7 3.80
CQS/HRH 100.0 0.85 95.3 0.65 107.7 0.71
CQS/TRH-EXP 116.2 3.00 98.5 1.22 99.4 0.75
CQS/HU-1 108.3 4.90 102.2 0.78 102.7 4.11
CQS/HU-7 107.8 4.60 98.5 0.3 97.6 6.33
CQS/HU-8 107.4 4.30 102.6 2.01 100.8 1.30
CQS/HU-9 109.9 1.20 98.1 0.83 95.9 9.15
CQS/PP-1 92.6 2.70 97.2 3.82 94.8 4.56
CQS/PP-2 90.7 2.50 102.6 2.10 96.4 2.10
CQS/PP-3 107.0 4.90 97.5 3.10 100.7 2.8
CQS/PP-4 98.0 4.30 101.3 2.10 99.7 1.45
CQS/PP-5 100.3 4.60 101.6 1.14 102.4 1.36
CENQAM = Centre for Quality Assurance of Medicine, South Africa
RSD = Relative standard deviation
DQCL = Drug Quality Control Laboratory
RMS = Regional Medical Store, Aden; GMS = Central Medical Stores, Lahej Governorate; DMS = District Medical Stores; GH = Governorate 
General Hospital; RH/HC = Rural Hospital/Health Centre; HU = Health Unit; PP = Private Pharmacy/Drug Store; exp = Expired; CQS = 
Chloroquine syrup.Malaria Journal 2005, 4:28 http://www.malariajournal.com/content/4/1/28
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tested. In general the % RSD for the pyrimethamine was
higher than for the sulfadoxine content in most of the
products.
The dissolution acceptance criteria for SPT of the USP
were applied. SPT have a Q-value of 60% in 30 minutes
for both actives and according to the acceptance table of
USP 2003:2161, the dissolution of each 6 units tested
should not be less than 65% (Q+5) for both the actives.
However, all products complied with the criteria with
regard to sulfadoxine, only two products complied with
the criteria for both actives.
The first product was found at Eskander private drug store
in Toben district (SPT/PP-1), which manufactured by
Intas Pharmaceuticals Ltd., India. The other product was
found at Al-Ikhlas private drug store in Al-Mosimir district
(SPT/PP-2), and manufactured by Roche, Switzerland.
The other products did not comply with the criteria for
pyrimethamine. Also only 1 unit of product SPT/CMS
[67.1% – 3.3 (% RSD) = 63.8%] did not comply with the
criteria for pyrimethamine(ç).
There was no significant difference between the national
DQC and CENQAM reference laboratories regarding the
active ingredients for CQS, CQT, and SPT, or CQT disso-
lution rate. On the other hand, there was a significant dif-
ference between them regarding the SP dissolution
whereby only 30% of SP tested were fulfilling the USP cri-
teria in CENQAM laboratory compared to all tested prod-
ucts in the national DQCLs (Table 3).
Table 4 shows a comparison between the quality of anti-
malarial drugs obtained from this study and that of 7
malaria endemic countries.
Discussion
The quality control performed in this study was utilized to
ensure that the batch of tested AMs complies with its spec-
ification and is fit for its intended in terms of efficacy,
safety and acceptability.
CQS had content failure rate of average 6.7%. The failure
was "high" failure. Content failure for CQT was very sig-
nificant and averaged at 20%. Failures were "low" and
"high" failures. SPT content complied with criteria with
respect to both actives in the 3 reference laboratories.
Table 3: Comparison between national reference laboratories and CENQAM Reference laboratory regarding the quality screening of 
AM drugs
CENQAM % ful-
filling the USP 
content criteria
Sana'a DQCL % 
fulfilling the USP 
content criteria
P1-value Aden DQCL % 
fulfilling the USP 
content criteria
P2-value P3-value
CQS Assay 93.3 (14/15) 100 (15/15) 1 100 (15/15) 1 1
CQT Assay 80 (20/25) 92 (23/25) 0.41 84 (21/25) 1 0.66
CQT dissolution 92 (23/25) 100 (25/25) 0.47 96 (24/25) 1 1
SP Assay 100 (10/10) 100 (10/10) 1 100 (10/10) 0 1
SPT dissolution 20 (2/10) 100 (10/10) 0.005* 100 (10/10) 0.005* 1
P1: p-value of Chi-Square test for comparing the proportion of tested products fulfilling the USP content criteria in CENQAM versus Sana'a 
reference laboratory.
P2: p-value of Chi-Square test for comparing the proportion of tested products fulfilling the USP content criteria in CENQAM versus Aden 
reference laboratory.
P3: p-value of Chi-Square test for comparing the proportion of tested products fulfilling the USP content criteria in Sana'a versus Aden reference 
laboratory.
Table 4: Comparison between country results: percentage failure of samples
Yemen Sudan Gabon Ghana Mali Kenya Mozambique Zimbabwe
CQS Assay 6.7 26.6 0 5.0 66.7 25.0 25.0 13.3
CQT assay 20 5.2 29.0 66.7 47.3 42.8 20.0 57.1
CQT dissolution 8 12.5 5.8 20.0 5.2 28.6 6.7 7.1
SP assay 0 0 0 37.5 0 0 5.5 10.0
SP dissolution 70 80 - 75.0 100 91.7 100 100Malaria Journal 2005, 4:28 http://www.malariajournal.com/content/4/1/28
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Dissolution failure rates for CQT were 8%. SPT had prob-
lems mostly with the dissolution of the pyrimethamine
component of the formulation, and averaged at 80% for
the SPT samples analysed.
The data presented in this report indicates there is a prob-
lem of sub-standard AMs available at the public health
facilities and circulating in the market. The main problem
seems to be samples below the lower limit of specifica-
tion. The most significant results were the low content
failures for CQT content and SPT dissolution. The failures
detected in this study indicate a serious problem that war-
rants further investigation and intervention.
Quality problems were not limited to a particular distri-
bution level but recorded at different levels. Also there
were failures among locally made products as well as for-
eign products. Further investigation of this phenomenon
will be important since it is easier for national drug regu-
latory authorities to act and correct problems that involve
domestic manufacturers.
The discrepancy between the national reference laborato-
ries and CENQAM results in ingredient content failure for
CQ and SPT dissolution, can only be taken as indicative,
but not conclusive and should be carefully investigated to
identify the causes and rectify them. As the three laborato-
ries use the same methodology for quality screening of
drugs, the possible reasons for such discrepancy could be
personnel errors and/or inadequate calibration of the
instruments used.
In comparison with other malaria endemic countries that
adopted the same methodology in evaluating the quality
of antimalarial drugs [9], the following comments could
be drawn from the study:
• CQS content failure in Yemen is relatively low and is
almost comparable to Ghana's. On the other hand, it is
significantly lower than other countries such as: Sudan,
Mali, Kenya, Mozambique and Zimbabwe.
• CQT content failure in Yemen is higher than Sudan,
comparable to Gabon, and Mozambique, but signifi-
cantly lower than Ghana, Mali, Kenya and Zimbabwe.
• CQT dissolution failure in Yemen is relatively low. It is
lower than Sudan, Ghana, Kenya, but comparable to
Gabon, Mali and Mozambique.
• SP content showed no failure, as in most other malaria
endemic countries. Similarly, SP dissolution failure was as
high as other malaria endemic countries.
Conclusion
Problems of sub-standard AMs exist in different studied
districts, within the drug distribution chain in Lahej,
Yemen and produced by both domestic and foreign
manufacturers.
Percentage failure of samples based on ingredient content
is 6.7% for CQS and 20% for CQT and in dissolution fail-
ure 8% for CQT and 70% for SPT, cannot be ignored. This
will have serious implications not only on the reduced
therapeutic effectiveness of AMs but also on the develop-
ment of drug resistance.
In view of potential danger that sub-standard AMs could
already be posing in the fight against malaria, an interven-
tion plan should be developed immediately. This could
involve setting up quality surveillance systems within
drug regulatory authorities in the country, supporting
manufacturers to improve Good Manufacturing Practice
(GMP) compliance and promote effective managing drug
supply.
The lessons learnt from this pilot study could be valuable
in any future investigations, and interventions to improve
the quality of AMs and other medicines in use in domestic
and international markets.
Recommendations
• Promoting good procurement practices in the public
sector by registration or pre-qualification of suppliers, i.e.
purchasing from reliable and approved sources.
• More emphasis should be given to testing for initial
quality, the routine testing of new supplies, ensuring
adherence of manufacturers and suppliers to GMP.
• Antimalarial drugs should be stored and distributed in
appropriate conditions in harbours, stores and health
facilities as well as at the level of the end users.
• Measures should be taken to stop the illegal importing
or smuggling of drugs.
• Ensure that people in charge of drug management sup-
ply and quality control are competent and receive train-
ing, a measure which would be cost-effective.
• Although the cost of antimalarial drugs is important,
good quality antimalarial drugs are more important than
cheaper poor drugs.
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